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Major molecular response to imatinib in a patient with chronic myeloid 
leukemia expressing a novel form of e8a2 BCR-ABL transcript 
 
A small proportion of patients with chronic myeloid leukemia (CML) express unusual 
types of BCR-ABL transcript. In a recent paper, Demehri et al1 pointed out that a 
BCR-ABL transcript with an e8a2 junction may be more frequent than other BCR-
ABL mRNA variants. Moreover, a review of eight so far described cases suggested 
that e8a2-positive CML might be more aggressive than CML with typical e13a2 and 
e14a2 BCR-ABL mRNAs. We report here a novel form of e8a2 BCR-ABL transcript in 
a CML patient who was treated with imatinib and monitored using real-time RT-PCR. 
A 43-year-old man was diagnosed with CML in August 2004. At presentation, 
the spleen was palpable (3 cm below costal margin). The hematological parameters 
were the following: white blood cells, 197 x 109/l with a differential count of 7% blasts, 
7% promyelocytes, 15% metamyelocytes, 23% myelocytes, 38% neutrophils, 3% 
eosinophils, 3% basophils, 1% monocytes, 3% lymphocytes; hemoglobin, 10.2 g/dl; 
platelet count, 91 x 109/l. The prognostic Sokal (1.09) and Hasford (862.6) scores 
were of intermediate risk. Cytogenetic and fluorescence in situ hybridization analyses 
showed the presence of t(9;22)(q34;q11) and BCR-ABL fusion gene in 100% of bone 
marrow metaphases. 
RT-PCR analysis for BCR-ABL mRNA was performed using primers enabling 
the detection of transcripts with e13a2, e14a2 and e1a2 BCR-ABL junctions. RT-PCR 
with e13a2/e14a2 primers was negative, whereas with e1a2 primers, an aberrant 
band of high molecular weight (>1 kb) was observed (Figure 1a). Sequencing 
revealed that this band corresponded to a junction between BCR exon e8 and ABL 
exon a2 including a 46-nucleotide stretch from BCR intron 8 at the fusion point 
(U07000 in GenBank, bases 108153 - 108198). This neo-exon in the BCR intron 8 is 
defined by cryptic donor and acceptor splice sites (Figure 1b). Using a new forward 
BCR e8 primer (5’-TCAATGAGGAGATCACACCCC-3’) and the ABL a2 reverse 
primer,2 we amplified a single fragment of expected size (173 bp) corresponding to 
this e8a2 transcript (Figure 1a). 
The splicing of BCR exon 8 to ABL exon 2 would not produce an oncogenic 
BCR-ABL protein due to a generation of a premature stop codon.1 In previously 
reported cases, the reading frame of e8a2 mRNA was correctly maintained by an 
insertion of intronic sequences generally derived from the ABL intron Ib or by 
breakpoints within the BCR exon 8. In the present case, a neo-exon from BCR intron 
8 was spliced between BCR exon e8 and ABL exon 2, giving rise to an in-frame e8a2 
BCR-ABL transcript. The recognition of these cryptic splicing sites, which are never 
used in the wild-type BCR gene, might simply result from new properties of the 
chimeric DNA fragment acquired during the re-organization of a neo-intron formed by 
BCR intron 8 and ABL intron 1. It is also possible that a second event such as a 
particular polymorphism or mutation activated one splicing enhancer in the vicinity of 
this neo-exon or altered the properties of a splicing factor that would able to 
recognize these particular splice sites with good efficiency. Overall, translocation 
breakpoints generating e8a2 fusions may be very infrequent or, in contrast, may 
occur relatively frequently, but as they lead to a truncated BCR-ABL protein, only rare 
CML cases that express in-frame e8a2 transcripts are detected. 
Clinically, e8a2-positive CML patients has no distinctive features at diagnosis.1 
In contrast to other reported patients with e8a2 BCR-ABL, who had a trend toward 
thrombocytosis, our patient presented with thrombocytopenia. Thrombocytopenia is 
occasionally found in untreated chronic phase CML. The mechanism is not clear, but 
it might be presumed that leukemia cells do not differentiate into the megakaryocytic 
lineage while normal progenitors are inhibited.3 Imatinib at standard dosage induced 
in the patient complete hematological and cytogenetical responses after 1 and 9 
months of treatment, respectively. Molecular monitoring was performed using real-
time RT-PCR with the BCR e8 primer, ABL primers and probe.4 The BCR-ABL/ABL 
ratio in blood cells was 93.1% at diagnosis, 63.4% after 3 months, 0.037% after 9 
months and 0.022% after 12 months of therapy. Thus, the patient has achieved a 
major molecular response (BCR-ABL/ABL ratio < 0.05%) within the first year of 
treatment, which is strongly predictive of a durable cytogenetic remission.5 Previously 
reported patients with e8a2 transcripts were resistant to interferon-alpha treatment, 
suggesting a worse prognosis of CML with e8a2 BCR-ABL.1 Our case provides 
evidence that e8a2 CML may be sensitive to the ABL tyrosine kinase inhibitor 
imatinib. More clinical observations and, perhaps, experimental studies of the protein 
translated from e8a2 BCR-ABL mRNA in a murine model may help to assess its 
leukemogenic activity and a possible influence on clinical course and outcome. 
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Figure legends 
 
Figure 1. 
(a) RT-PCR for BCR-ABL mRNA with e1a2 primers (lanes 1-4) and e8a2 primers 
(lanes 5-7). Patient’s bone marrow (lanes 1 and 5) and peripheral blood 
samples (lanes 2 and 6). The arrow indicates large amplification products (> 1 
kb) detected with e1a2 primers. Lane 3, positive control for e1a2 transcript 
(244 bp); lanes 4 and 7, blank controls; lane M, PCR markers (Promega). 
(b) Schematic representation and sequence of BCR-ABL junction in the mRNA of 
the patient. Solid lines indicate the splicing between BCR exon 8, neo-exon 
from BCR intron 8 and ABL exon 2, which occurred in the patient’s mRNA. 
Dotted lines indicate an expected splicing between BCR exon 8 and ABL 
exon 2. Below, the first line is the sequence of the 3’ end of BCR exon e8 and 
of the 5’ end of ABL exon 2, the second line is the sequence of the neo-exon 
from BCR intron 8 and the third line is the sequence of acceptor and donor 
splice sites surrounding this new exon. Canonical dinucleotides GT and AG at 
the 5’ and 3’ intron boundaries are given in bold. The scores for the splice 
sites calculated using the splice site detector program NetGene2 are 
indicated. 
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